TLR9 and neoplasm: Finally, differentiation of suppressive MDSCs into mature myeloid cells (including macrophages and DCs) through treatment with Vitamin D3 [293], all-trans-retinoic acid (ATRA) [294], taxanes (docetaxel and paclitaxel) [295], TLR9 activation (CpG) [296], curcumin [297], whole-glucan particles (WGP) [298], and casein kinase inhibitor (tetrabromocinnamic acid) [299] can overtly modulates MDSCs and decrease the tumor growth in tumor-bearing mice and cancer patients.